Blossomhill Therapeutics Inc BLSM

$14.02 -0.82 (-5.53%)

Valuation

Market cap
445,626,000
Revenue TTM
$0
Net income TTM
$-60,560,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
222,500
Avg volume
199,668
Day's range
$13.40 – $15.68
Shares out
31,785,000
Stochastic %K
58%
Beta
—
Analysts
Strong Buy
Price target
$35.40

Price

Company profile

BlossomHill Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecule medicines that address medical needs in cancer treatment. Its pipeline includes BH-30643, an OMNI-EGFR inhibitor in clinical development for advanced EGFR-mutant non-small cell lung cancer (NSCLC), BH-501284, and BH-30236, a macrocyclic CLK (Cdc2-like kinase) inhibitor being evaluated in patients with relapsed or refra...

Show more

BlossomHill Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecule medicines that address medical needs in cancer treatment. Its pipeline includes BH-30643, an OMNI-EGFR inhibitor in clinical development for advanced EGFR-mutant non-small cell lung cancer (NSCLC), BH-501284, and BH-30236, a macrocyclic CLK (Cdc2-like kinase) inhibitor being evaluated in patients with relapsed or refractory acute myeloid leukemia (R/R AML) and higher-risk myelodysplastic syndrome (HR-MDS). BlossomHill Therapeutics, Inc. was incorporated in 2020 and is based in San Diego, California.

Industry
Biotechnology
Sector
Healthcare
Phone
(858) 732-3880
Website
https://bhtherapeutics.com
Address
10255 Science Center Drive, Suite 200, San Diego, United States

Latest news

No headlines yet.